Insys Therapeutics (INSY) Tops Q3 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St rises as Anthropic's IPO filing sharpens focus on AI trade
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts INSY Hot Sheet
Join SI Premium – FREE
Insys Therapeutics (NASDAQ: INSY) reported Q3 EPS of $0.50, $0.27 better than the analyst estimate of $0.23. Revenue for the quarter came in at $91.3 million versus the consensus estimate of $82.98 million.
For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 1st Source (SRCE) PT Raised to $92 at KBW After a 'High Quality Result'
- Kaiser Aluminum Corporation (KALU) PT Lowered to $127 at KeyBanc
- Jefferies Names Top European Mid-Cap IT Stocks After the Latest Update
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
